Nrx pharmaceuticals announces fda permission to proceed on investigational new drug (ind) application for nrx-101 to treat chronic pain

Allows initiation of the nrx-101 commercial development to treat chronic pain company plans to seek fast track and breakthrough therapy designations from fda while awaiting near-term results of dept of defense-funded trial radnor, pa. , oct. 2, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced that fda has given the company clearance to proceed with human trials to treat chronic pain under the investigational new drug (ind) application filed with the u.s. food and drug administration (fda) for the use of nrx-101.
NRXP Ratings Summary
NRXP Quant Ranking